Investor News
Accelus Receives U.S. FDA 510(k) Clearance for its FlareHawk TiHawk11 Interbody Fusion System
May 12, 2022
No Comments
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) – Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive
Accelus Launches TiHawk7™ Titanium-Bonded Multidirectionally Expanding Interbody Cage to Support Endoscopic and MIS Lumbar Fusion Procedures
May 5, 2022
No Comments
TiHawk7 combines ultra-low 7mm insertion profile with strong titanium/PEEK adhesion while still allowing for radiographic verification of fusion PALM BEACH GARDENS, Fla., May 5, 2022
Sun Sentinel Names Accelus a Winner of the South Florida Top Workplaces 2022 Award
May 2, 2022
No Comments
Leading medical technology company recognized for employee engagement and culture PALM BEACH GARDENS, Fla., May 02, 2022 (GLOBE NEWSWIRE) — Accelus, a privately held medical
Accelus Investor Contact
Brian Johnston (Gilmartin Group)
ir@accelusinc.com
View the investor disclaimer below:
ir@accelusinc.com
View the investor disclaimer below: